Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature.

Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G.

Int J Radiat Biol. 2018 Dec 17:1-29. doi: 10.1080/09553002.2019.1558301. [Epub ahead of print]

PMID:
30557063
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.

Int J Clin Oncol. 2018 Feb;23(1):173-180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2.

4.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
5.

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.

Nilsson S.

Expert Opin Drug Saf. 2015 Jul;14(7):1127-36. doi: 10.1517/14740338.2015.1045874. Epub 2015 May 28.

PMID:
26022669
6.

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

Vogelzang NJ.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):809-819. doi: 10.1080/17512433.2017.1345624. Epub 2017 Jul 3. Review.

PMID:
28649893
7.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

8.

Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.

Ojo D, Lin X, Wong N, Gu Y, Tang D.

Cancers (Basel). 2015 Nov 18;7(4):2290-308. doi: 10.3390/cancers7040890. Review.

10.

Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.

Tilki D, Schaeffer EM, Evans CP.

Eur Urol Focus. 2016 Dec;2(5):499-505. doi: 10.1016/j.euf.2016.11.013. Epub 2016 Dec 9. Review.

11.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17. Review.

12.

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.

Uemura H, Uemura H, Matsubara N, Kinuya S, Hosono M, Yajima Y, Doi T.

Int J Clin Oncol. 2017 Oct;22(5):954-963. doi: 10.1007/s10147-017-1130-1. Epub 2017 May 6.

13.

Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.

McGann S, Horton ER.

Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Epub 2015 Jan 8. Review.

PMID:
25573268
14.

Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.

Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.

Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.

PMID:
27550197
15.

Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Suzman DL, Antonarakis ES.

Ther Adv Med Oncol. 2014 Jul;6(4):167-79. doi: 10.1177/1758834014529176. Review.

16.

Radium Ra 223 dichloride in castration-resistant prostate cancer.

Joung JY, Ha YS, Kim IY.

Drugs Today (Barc). 2013 Aug;49(8):483-90. doi: 10.1358/dot.2013.49.8.1968670.

PMID:
23977665
17.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
18.

Practical guide to the use of radium 223 dichloride.

Den RB, Doyle LA, Knudsen KE.

Can J Urol. 2014 Apr;21(2 Supp 1):70-6. Review.

19.

Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.

Shirley M, McCormack PL.

Drugs. 2014 Apr;74(5):579-86. doi: 10.1007/s40265-014-0198-4. Review.

PMID:
24610703
20.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952

Supplemental Content

Support Center